Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 3/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349181 | 1.00 | MEN1 (0.52) | MEN1KMT2AALDH1A1MAPTGRM1 | |
| SCHEMBL3348697 | 0.94 | L3MBTL1 (0.46) | MEN1KMT2AALDH1A1MAPTGRM1 | |
| SCHEMBL3348690 | 0.94 | L3MBTL1 (0.46) | MEN1KMT2AALDH1A1MAPTGRM1 | |
| SCHEMBL3346661 | 0.94 | MEN1 (0.53) | MEN1KMT2AALDH1A1MAPTGRM1 | |
| SCHEMBL3346672 | 0.94 | MEN1 (0.53) | MEN1KMT2AALDH1A1MAPTGRM1 | |
| SCHEMBL3347410 | 0.93 | MEN1 (0.54) | MEN1KMT2AALDH1A1MAPTGRM1 | |
| SCHEMBL3347415 | 0.93 | MEN1 (0.54) | MEN1KMT2AALDH1A1MAPTGRM1 | |
| SCHEMBL3420640 | 0.92 | MEN1 (0.50) | MEN1KMT2AALDH1A1MAPTGRM1 | |
| SCHEMBL3420642 | 0.92 | MEN1 (0.50) | MEN1KMT2AALDH1A1MAPTGRM1 | |
| SCHEMBL3417902 | 0.91 | MEN1 (0.53) | MEN1KMT2AALDH1A1MAPTGRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741488-B2 | Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer | 4SC AG (DE) | 2010-06-22 | — | — | US | claimed |
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | PEKARI KLAUS | 2009-10-08 | — | — | US | claimed |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | ALTANA PHARMA AG (DE) | 2009-04-16 | — | — | US | claimed |
| EP-1851230-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2007-11-07 | — | — | EP | claimed |
| WO-2006084904-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | claimed |
| US-7741488-B2 | Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer | 4SC AG (DE) | 2010-06-22 | — | — | US | disclosed |
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | PEKARI KLAUS | 2009-10-08 | — | — | US | disclosed |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | ALTANA PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-1851230-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006084904-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | RAB1A, RAB7A, RAB35 | MEN1 3675/4885KMT2A 1827/4885ALDH1A1 1497/4885 |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | MKI67, BCL2, BAX | MEN1 3685/4885KMT2A 2436/4885ALDH1A1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.